Inovio Pharmaceuticals
118 hedge funds and large institutions have $95.2M invested in Inovio Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 36 increasing their positions, 31 reducing their positions, and 16 closing their positions.
16% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 31
0.01% more ownership
Funds ownership: 3.89% → 3.9% (+0.01%)
6% less funds holding
Funds holding: 126 → 118 (-8)
29% less capital invested
Capital invested by funds: $135M → $95.2M (-$39.3M)
43% less call options, than puts
Call options by funds: $71K | Put options by funds: $124K
50% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 16
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NAMA
Nikko Asset Management Americas
New York
|
+$690K |
| 2 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$690K |
| 3 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$678K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$638K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$293K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IG
ING Group
Amsterdam,
Netherlands
|
-$429K |
| 2 |
D.E. Shaw & Co
New York
|
-$368K |
| 3 |
Two Sigma Investments
New York
|
-$265K |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$263K |
| 5 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$236K |
INO Hedge Fund Activity: Q3 2019 in Review
118 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Inovio Pharmaceuticals (INO) for Q3 2019, worth a combined $95.2M — down 29% from $135M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of INO and 8 opened new positions — a net loss of 8 holders — while 31 trimmed existing stakes and 36 added.
The largest buyer was Nikko Asset Management Americas, adding an estimated $690K. The largest seller was ING Group, exiting entirely with an estimated $429K sold.
- 118 institutional investors held Inovio Pharmaceuticals (INO) as of Q3 2019, down from 126 in Q2 2019.
- Funds reported $95.2M of Inovio Pharmaceuticals stock for Q3 2019, down 29% quarter-over-quarter.
- 8 funds opened new Inovio Pharmaceuticals positions in Q3 2019 and 16 closed out, a net change of -8 holders.
- The largest Inovio Pharmaceuticals buyer in Q3 2019 was Nikko Asset Management Americas, an estimated $690K added.
- The largest Inovio Pharmaceuticals seller in Q3 2019 was ING Group, an estimated $429K sold.
Based on aggregated 13F filings for Q3 2019.